Anti-inflammatory salicylate beneficially modulates pre-existing atherosclerosis through quenching of NF-κB activity and lowering of cholesterol

Atherosclerosis

Volumn 213, Issue 1, 2010, Pages 241-246

  de Vries van der Weij, Jitske ^a,b   Toet, Karin ^a   Zadelaar, Susanne ^a   Wielinga, Peter Y ^a   Kleemann, Robert ^a   Rensen, Patrick C N ^b   Kooistra, Teake ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti inflammatory treatment; Established lesions; Inflammation; Mouse model of atherosclerosis; NF B; On top of statin treatment; Reduce further progression of atherosclerosis; Serum amyloid A (SAA); Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SALICYLIC ACID; SERUM AMYLOID A; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AORTA; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; HISTOLOGY; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIVER; LOW FAT DIET; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA; ATHEROSCLEROSIS; CHOLESTEROL; DISEASE MODELS, ANIMAL; FEMALE; INFLAMMATION; MACROPHAGES; MICE; MICE, TRANSGENIC; NF-KAPPA B; SALICYLATES; STAT3 TRANSCRIPTION FACTOR; TREATMENT OUTCOME;

EID: 77958508103     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.09.006     Document Type: Article

References (28)

1. Steinberg D. Hypercholesterolemia and inflammation in atherogenesis: two sides of the same coin. Mol Nutr Food Res 2005, 49:995-998.
2. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
3. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
4. Davis H.R., Compton D.S., Hoos L., et al. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2001, 21:2032-2038.
5. Kleemann R., Princen H.M., Emeis J.J., et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 2003, 108:1368-1374.
6. Mach F., Schonbeck U., Sukhova G.K., et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998, 394:200-203.
7. Verschuren L., Kleemann R., Offerman E.H., et al. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol 2005, 25:161-167.
8. Gijbels M.J., van der Cammen M., van der Laan L.J., et al. Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study. Atherosclerosis 1999, 143:15-25.
9. Tsukamoto K., Tangirala R., Chun S.H., et al. Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999, 19:2162-2170.
10. Verschuren L., de Vries-van der Weij, Zadelaar S., et al. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice:time course and mechanisms. J Lipid Res 2009, 50:301-311.
11. Trogan E., Feig J.E., Dogan S., et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci USA 2006, 103:3781-3786.
12. Gottlieb I., Agarwal S., Gautam S., et al. Aortic plaque regression as determined by magnetic resonance imaging with high-dose and low-dose statin therapy. J Cardiovasc Med (Hagerstown) 2008, 9:700-706.
13. Bernhagen J., Krohn R., Lue H., et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007, 13:587-596.
14. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396:77-80.
15. Kleemann R., Verschuren L., van Erk M.J., et al. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol 2007, 8:R200.
16. Zadelaar S., Kleemann R., Verschuren L., et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007, 27:1706-1721.
17. Westerterp M., de Haan W., Berbee J.F., Havekes L.M., Rensen P.C. Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL. J Lipid Res 2006, 47:1203-1211.
18. Kooistra T., Verschuren L., de Vries-van der Weij, et al. Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. Arterioscler Thromb Vasc Biol 2006, 26:2322-2330.
19. de Vries-van der Weij J., Zadelaar S., Toet K., et al. Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice. Atherosclerosis 2009, 206:153-158.
20. Pfitzner E., Kliem S., Baus D., et al. The role of STATs in inflammation and inflammatory diseases. Curr Pharm Des 2004, 10:2839-2850.
21. Viles-Gonzalez J.F., Fuster V., Corti R., et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition-a magnetic resonance imaging study. Eur Heart J 2005, 26:1557-1561.
22. Kanters E., Pasparakis M., Gijbels M.J., et al. Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2003, 112:1176-1185.
23. Kanters E., Gijbels M.J., van der Made I., et al. Hematopoietic NF-kappaB1 deficiency results in small atherosclerotic lesions with an inflammatory phenotype. Blood 2004, 103:934-940.
24. Wolfrum S., Teupser D., Tan M., et al. The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression of NF-kappaB target genes. Proc Natl Acad Sci USA 2007, 104:18601-18606.
25. Cyrus T., Sung S., Zhao L., et al. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2002, 106:1282-1287.
26. Chen T., Guo J., Yang M., et al. Cyclosporin A impairs dendritic cell migration by regulating chemokine receptor expression and inhibiting cyclooxygenase-2 expression. Blood 2004, 103:413-421.
27. Bellas R.E., FitzGerald M.J., Fausto N., et al. Inhibition of NF-kappa B activity induces apoptosis in murine hepatocytes. Am J Pathol 1997, 151:891-896.
28. Kleemann R., van Erk M., Verschuren L., et al. Time-resolved and tissue-specific systems analysis of the pathogenesis of insulin resistance. PLoS One 2010, 5(1):e8817.